Mebendazole Disrupts Nucleotide Metabolism in Gastric Cancer (2026)
A 2026 preclinical study shows mebendazole impairs nucleotide metabolism enzymes in gastric cancer cells, causing cell cycle arrest and antiproliferative activity comparable to 5-FU with lower toxicity to normal cells. Laboratory evidence only.
By Sanare Lab · August 8, 2026 · 5 min read
Key Takeaway
A 2026 study in Chemico-Biological Interactions reveals that mebendazole impairs nucleotide metabolism enzymes including PRPS1, TYMS, MTHFD1, and HPRT1 in gastric cancer (GC) cells. This disruption of DNA and RNA synthesis pathways led to G0/G1 phase cell cycle arrest and showed antiproliferative activity comparable to 5-fluorouracil (5-FU) with lower toxicity to non-tumor cells. Molecular docking confirmed mebendazole binds more strongly to key nucleotide enzymes than natural ligands. This is preclinical laboratory evidence, not human clinical data.
Gastric cancer (GC) remains one of the leading causes of cancer-related deaths worldwide. The standard chemotherapy 5-fluorouracil (5-FU) targets nucleotide metabolism to block DNA and RNA synthesis, but it carries significant toxicity to normal tissues. Drug repurposing seeks to find existing medications with anticancer activity and better safety profiles.
Mebendazole, an antiparasitic benzimidazole drug, has shown anticancer effects in multiple tumor models including glioblastoma, medulloblastoma, and colorectal cancer. Its mechanisms include microtubule disruption, glucose metabolism inhibition, and immunomodulation. A 2026 study in Chemico-Biological Interactions adds a new mechanism: mebendazole impairs nucleotide biosynthesis, a critical pathway for tumor cell replication.
Table of Contents
- Nucleotide Metabolism in Cancer
- Study Methods and Targets
- Gene Expression and Survival Data
- Cell Cycle Arrest and Proliferation
- Molecular Docking Results
- Limitations and Evidence Level
- Frequently Asked Questions
Nucleotide Metabolism in Cancer
Nucleotide biosynthesis is the process by which cells make the building blocks of DNA and RNA. Rapidly dividing cancer cells have extremely high demand for nucleotides, making this pathway an attractive therapeutic target. Drugs like 5-FU and methotrexate have been used for decades to block nucleotide synthesis, but they are associated with significant side effects because they also affect normal tissues with high turnover, such as bone marrow and the gut lining.
The key enzymes in this pathway include PRPS1 (phosphoribosyl pyrophosphate synthetase 1), TYMS (thymidylate synthase), MTHFD1 (methylenetetrahydrofolate dehydrogenase), and HPRT1 (hypoxanthine phosphoribosyltransferase 1). Overexpression of these enzymes in tumors is often associated with aggressive disease and poor patient survival.
Study Methods and Targets
The 2026 study investigated whether mebendazole could target nucleotide metabolism in gastric cancer. The researchers used:
- Gastric cancer cell lines to test antiproliferative effects.
- Gene expression analysis to measure levels of nucleotide metabolism enzymes before and after mebendazole treatment.
- Cell cycle analysis to determine which phase of the cell cycle was arrested.
- Molecular docking to predict how mebendazole physically interacts with key enzyme targets at the molecular level.
The comparison drug was 5-fluorouracil (5-FU), the standard chemotherapy for gastric cancer, to benchmark mebendazole's potency and toxicity profile.
Gene Expression and Survival Data
The researchers first analyzed tumor samples and found that PRPS1, TYMS, MTHFD1, and HPRT1 were overexpressed in gastric cancer compared to normal tissue. Higher expression of TYMS, MTHFD1, and HPRT1 was associated with poorer overall survival in gastric cancer patients, confirming these enzymes as clinically relevant targets.
After mebendazole treatment, the expression of all four nucleotide metabolism genes was significantly reduced in gastric cancer cells. This indicates that mebendazole acts upstream of DNA synthesis by limiting the supply of raw materials needed for replication.
Cell Cycle Arrest and Proliferation
The functional consequences of nucleotide depletion were clear:
- G0/G1 phase cell cycle arrest: Mebendazole treatment caused cells to stop progressing from the G1 (growth) phase to the S (DNA synthesis) phase, where replication occurs. This is a classic response to nucleotide shortage.
- Antiproliferative activity comparable to 5-FU: Mebendazole showed antitumor activity similar to 5-FU in gastric cancer cells.
- Lower toxicity to non-tumor cells: Unlike 5-FU, mebendazole was less toxic to normal (non-tumor) cells, suggesting a more selective effect.
- Metastatic proliferation inhibition: After 48 hours of treatment, mebendazole inhibited the proliferation of metastatic gastric cancer cells.
Molecular Docking Results
To understand the physical interaction, the researchers performed molecular docking simulations. These computational models predict how a small molecule fits into the binding pocket of a target protein. The results showed that:
- Mebendazole binds more strongly to PRPS1 and HPRT1 than their natural substrates or known inhibitors, suggesting it could outcompete normal ligands for the enzyme active site.
- The binding poses are consistent with competitive inhibition, where mebendazole occupies the enzyme's active pocket and prevents normal catalytic activity.
This molecular-level evidence supports the observed gene expression and cell-cycle changes, linking mebendazole's anticancer effect to a specific biochemical mechanism.
Limitations and Evidence Level
This study is preclinical it used gastric cancer cell lines and computational docking, not animal models or human patients. Key limitations include:
- Cell lines do not fully replicate the complexity of a real tumor, including the immune system, stroma, and drug metabolism.
- Optimal dosing, pharmacokinetics, and bioavailability in humans are unknown.
- Combination effects with standard gastric cancer therapies (e.g., 5-FU, cisplatin, oxaliplatin) have not been tested.
- Clinical trials would be required before any human use could be considered.
The study highlights a promising new mechanism for mebendazole in cancer but does not establish clinical efficacy or safety.
For background, see our guide to how fenbendazole compares with mebendazole.
You can map out a weight-based schedule using our dosage calculator.
Frequently Asked Questions
What is nucleotide metabolism and why is it important in cancer?
Nucleotide metabolism is the process cells use to make DNA and RNA building blocks. Cancer cells divide rapidly and need large amounts of nucleotides, so blocking this pathway can stop tumor growth. Standard chemotherapy drugs like 5-fluorouracil (5-FU) target this pathway, but they also harm normal fast-dividing tissues like bone marrow and the gut lining.
What are PRPS1, TYMS, MTHFD1, and HPRT1?
These are enzymes in the nucleotide biosynthesis pathway. PRPS1 (phosphoribosyl pyrophosphate synthetase 1) makes a precursor molecule. TYMS (thymidylate synthase) builds thymidine for DNA. MTHFD1 (methylenetetrahydrofolate dehydrogenase) provides one-carbon units for nucleotide synthesis. HPRT1 (hypoxanthine phosphoribosyltransferase 1) recycles purine bases. Overexpression of these enzymes in tumors correlates with worse survival.
What is molecular docking and what did it show?
Molecular docking is a computer simulation that predicts how a small drug molecule fits into the binding pocket of a target protein. In this study, docking showed that mebendazole binds more tightly to PRPS1 and HPRT1 than their natural substrates or known inhibitors, suggesting it could block these enzymes by occupying their active sites.
Can mebendazole replace 5-FU for gastric cancer?
No. This study is laboratory evidence only. While mebendazole showed comparable antiproliferative activity to 5-FU in cell lines with less toxicity to normal cells, there are no animal or human data. 5-FU remains a standard chemotherapy for gastric cancer. Any changes to treatment must be decided by a qualified oncologist based on clinical evidence.
Cancer cells need to make DNA and RNA building blocks very quickly to keep dividing. This study found that mebendazole, an antiparasitic drug, blocks the enzymes that make these building blocks in stomach cancer cells. When the cells run out of raw materials for DNA copying, they get stuck in the growth phase and stop multiplying. In lab tests, mebendazole worked about as well as standard chemotherapy (5-FU) but was less harmful to normal cells. Computer models also showed it fits tightly into the enzyme pockets. This is only laboratory evidence, not a treatment for human patients.
Shop Sanare Lab
Lab-tested products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.
Lab-tested purity. 222 mg capsules, 90 count.
High-bioavailability curcumin, 120 capsules.
Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.
References
- Li et al. (2026). Mebendazole impairs the expression and function of enzymes in nucleotide metabolism pathways, leading to Selective Cytotoxicity, Cell Cycle Arrest, and Damage to Cell Morphology in Gastric Cancer. Chemico-Biological Interactions. PubMed
Medical Disclaimer
This article is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.